Immunonkologie - ein Überblick

Keyphrases

• Anti-CD19 50%
• B-cell Leukemia 50%
• B-cell Lymphoma 50%
• Bispecific Antibody 50%
• Blinatumomab 50%
• Cancer Patients 50%
• Cancer Types 50%
• CD19 50%
• Cell Therapy 50%
• Chimeric Antigen Receptor T Cells (CAR-T) 50%
• Clinical Development 50%
• Cytotoxic T-lymphocyte antigen-4 (CTLA-4) 50%
• Genetic Engineering 50%
• Immune System 50%
• Immuno-oncology 100%
• Immunotherapeutic Approaches 50%
• Inhibitory Antibody 50%
• Lymphatics 50%
• Malignant B Cells 50%
• Melanoma Cells 50%
• Metastatic Melanoma 50%
• Non-small Cell Lung Cancer (NSCLC) 50%
• Overall Survival 50%
• Programmed Death-ligand 1 (PD-L1) 50%
• Response Rate 50%
• Standard of Care 50%
• Successful Implementation 50%
• T Cell Activation 50%
• T Cells 100%
• Treatment Modalities 50%
• Tumor Control 50%
• Tumor Disease 50%

Medicine and Dentistry

• Acute Lymphocytic Leukemia 100%
• B Cell Leukemia 50%
• B-Cell Lymphoma 50%
• Bispecific Antibody 50%
• Blinatumomab 50%
• Cancer Types 50%
• CD3 Antigen 50%
• Chimeric Antigen Receptor 50%
• CTLA-4 50%
• Diseases 50%
• Immune System 50%
• Immunoglobulin 100%
• Immunotherapy 100%
• Lymph Duct 50%
• Malignant Neoplasm 100%
• Metastatic Melanoma 50%
• Neoplasm 100%
• Non Small Cell Lung Cancer 50%
• Oncology 100%
• Overall Survival 50%
• Programmed Death-Ligand 1 50%
• Receptor 50%
• Side Effect 50%
• T Cell 100%
• T Cell Activation 50%
• Treatment Modality 50%

Pharmacology, Toxicology and Pharmaceutical Science

• B Cell Leukemia 33%
• B Cell Lymphoma 33%
• Bispecific Antibody 33%
• Blinatumomab 33%
• CD3 Antigen 33%
• Chimeric Antigen Receptor 33%
• Cytotoxic T Lymphocyte Antigen 4 33%
• Diseases 33%
• Immunoglobulin 100%
• Immunotherapy 66%
• Malignant Neoplasm 100%
• Metastatic Melanoma 33%
• Neoplasm 66%
• Non Small Cell Lung Cancer 33%
• Overall Survival 33%
• Receptor 33%
• Side Effect 33%